GPR68 is a proton-sensing G-protein coupled receptor implicated in tumour biology, but its role in human melanoma remains poorly understood. This study aimed to evaluate the clinical significance, prognostic value, and potential functional role of GPR68 expression in cutaneous melanoma. A secondary analysis was conducted using publicly available RNA sequencing and clinical data from 439 melanoma tumours (TCGA-SKCM) and 76 unrelated melanoma cell lines (Sequence Read Archive). GPR68 expression was compared between tumours and cell lines, and assessed for associations with patient demographics, sample type, disease-specific survival, CD8+ T cell abundance, and gene set enrichment pathways. GPR68 expression was significantly higher in melanoma tumours than in melanoma cell lines (p < 0.001). Within tumours, expression did not differ significantly by sex, age group, or sample type. Higher GPR68 expression was associated with prolonged disease-specific survival (p = 0.040) and increased CD8+ T cell abundance (p < 0.001), which remained the only significant predictor in a general linear model including other clinical variables (p < 0.001). Gene set enrichment analysis showed that tumours with high GPR68 expression were enriched for immune signalling pathways, while those with low expression were enriched for proliferative and metabolic pathways (FDR q < 0.05). These findings suggest that GPR68 expression in melanoma is associated with favourable prognostic features, including tumour immunogenicity and improved survival. Further studies are needed to determine GPR68 cell-type expression and function in melanoma tumours, before its therapeutic relevance can be evaluated.